TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05132595

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine at high dose
Description: After the induction of anesthesia, esketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h esketamine until starting skin suture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine at low dose
Description: After the induction of anesthesia, esketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h esketamine until starting skin suture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac at high dose
Description: After the induction of anesthesia, Ketorolac is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h Ketorolac until starting skin suture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac at low dose
Description: After the induction of anesthesia, Ketorolac is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h Ketorolac until starting skin suture.
Study: NCT05054231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: Blood samples collection: at Day (D)-6 and D0 before CAR-T cells injection, post injection at Day (D)3, D5,D7, D9, D11, D14, D18, D 21, Month 2 and Month 12 post injection.
Study: NCT06261476

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ashwagandha (Withnia somnifera)
Description: Ashwagandha is the active ingredient in Withania somnifera (a medicinal plant in Indian medicine). Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
Study: NCT05668026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: In this study participants will receive venetoclax 200 mg, 400 mg or 800 mg once daily for 14 days in the dose-escalation phase. In the expansion cohort, the selected max-tolerated dose will be given for three cycles, each consisting of venetoclax daily for 14 days followed by 14 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: In this study participants will receive venetoclax 200 mg, 400 mg or 800 mg once daily for 14 days in the dose-escalation phase. In the expansion cohort, the selected max-tolerated dose will be given for three cycles, each consisting of venetoclax daily for 14 days followed by 14 days off.
Study: NCT05369533

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Telerehabilitation
Description: The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation
Description: The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet Pill
Description: Sinemet 25/100 will be taken 1 hour prior to TR, for the first 18 sessions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken 1 hour prior to TR, for the first 18 sessions.
Study: NCT06790342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched to cystine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched to cystine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standardized brief advice to quit smoking (standard of care)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standardized brief advice to quit smoking (standard of care)
Study: NCT05338658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peptide Alarm Therapy (PAT)
Description: PAT is given on Day 1 by IT injection after the 1st anti PD-1/PD-L1 infusion and again 36-48 hours later on Day 3.
Study: NCT06133985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Costovertebral mobilizations + Conventional PT
Description: Costovertebral mobilizations along conventional treatment patient would receive costovertebral mobilization in side lying position for 10th to 6th ribs, in sitting position for 10th to 2nd rib and in supine position for 1 rib.~Frequency: 5 times/week for 3 weeks. Intensity: moderate intensity (pain free) Time: 10 mins Type: costovertebral joint mobilization to improve respiratory function and chest tightness.~Conventional treatment diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional treatment
Description: diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness.
Study: NCT05013294

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intervention
Description: Text messages through a basic phone or smart phone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Text messages through a basic phone or smart phone
Study: NCT05820646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boswellia Sacra
Description: 1. Boswellia Sacra used as an intracanal medicament for 3 days~2. Boswellia Sacra used as an intracanal medicament for 7 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Boswellia Sacra
Description: 1. Boswellia Sacra used as an intracanal medicament for 3 days~2. Boswellia Sacra used as an intracanal medicament for 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boswellia Sacra
Description: 1. Boswellia Sacra used as an intracanal medicament for 3 days~2. Boswellia Sacra used as an intracanal medicament for 7 days
Study: NCT05482412

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcutaneous (superficial) afferent electrical nerve stimulation specific for vagus nerve
Description: Direct superficial auricular sensory branch of Cr X \[Cranial Nerve Ten Vagus\]
Study: NCT06122246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW)
Description: Participants will receive the additional support of a Community Health Worker (CHW).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Blood Pressure (BP) Management Program (RBPM)
Description: Participants will receive a medical model of remote BP management (RBPM).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Blood Pressure (BP) Management Program (RBPM)
Description: Participants will receive a medical model of remote BP management (RBPM).
Study: NCT06310837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Biosimilars Injection
Description: Adalimumab biosimilars: 80 mg was subcutaneously injected for the first time in the first week, and then 40 mg was subcutaneously injected every two weeks from the first week to the 48 th week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Patients received no less than 1 mg / kg.d glucocorticoid at week 0, then implemented according to the standard reduction scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressive Agents
Description: Mycophenolate mofetil 1g bid for more than 3 months, maintenance dose not less than 0.5g bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunosuppressive Agents
Description: Mycophenolate mofetil 1g bid for more than 3 months, maintenance dose not less than 0.5g bid
Study: NCT03874416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific rehabilitation
Description: Experimental rehabilitation of working memory:~3 sessions per week during 3 months, for a total 36 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-specific rehabilitation
Description: Usual non-specific rehabilitation treatment for moderate to severe TBI in healthcare facilities: 2-3 sessions per week for 3 months.
Study: NCT06508970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental RAM-based virtual reality glasses
Description: RAM-based virtual reality glasses were applied to the experimental group for 4 weeks.~Video contents:~1. week; 1st sub-dimension (physiological domain)~2. weeks; 2nd sub-dimension (self-space) Three weeks; 3rd sub-dimension (Role function/function area) week 4; 4th sub-dimension (Independence and interdependence/autonomy)

Intervention type: OTHER
Group type: OTHER
Intervention: pre-post test
Description: Adaptation Difficulty Assessment Scale in the Elderly, Life Satisfaction Scale in the Elderly , and Psychological Well-Being Scale in the Elderly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pre-post test
Description: Adaptation Difficulty Assessment Scale in the Elderly, Life Satisfaction Scale in the Elderly , and Psychological Well-Being Scale in the Elderly
Study: NCT05263544

Intervention type: OTHER
Intervention: measuring uterocervical angle and uterine dimensions
Description: in both groups with and without displaced IUD, uterus size, uterine width, cervical canal length, endometrial canal length, endometrial canal width, and the angle at the intersection of the imaginary lines corresponding to the middle of the endometrium and cervical canal, which can be detected by transvaginal ultrasound will be measured

Intervention type: OTHER
Intervention: measuring uterocervical angle and uterine dimensions
Description: in both groups with and without displaced IUD, uterus size, uterine width, cervical canal length, endometrial canal length, endometrial canal width, and the angle at the intersection of the imaginary lines corresponding to the middle of the endometrium and cervical canal, which can be detected by transvaginal ultrasound will be measured
Study: NCT04231032

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asynchronous dual chamber pacing (DOO) with paced ventricular activation
Description: Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Asynchronous atrial pacing (AOO) with intrinsic ventricular activation
Description: Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
Study: NCT04673669

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Posterior tibial tendon strength mesure
Description: Posterior tibial tendon strength is assessed with a hand-held dynamometer by two independent observer and with an isometric dynamometer by one observer.
Study: NCT05957848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine Extended Release Oral Tablet
Description: Target dose 4 mg daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Residential withdrawal
Description: 4-14 days in residential withdrawal treatment

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Residential withdrawal
Description: 4-14 days in residential withdrawal treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement with alcohol and other drug services
Description: Ongoing engagement with a youth drug and alcohol service for counselling or other support for the duration of the study

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Engagement with alcohol and other drug services
Description: Ongoing engagement with a youth drug and alcohol service for counselling or other support for the duration of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule taken daily
Study: NCT04843943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200mg IV Q3W D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Biosimilar
Description: Bevacizumab biosimilar: 15mg/kg, IV, Q3W, D1
Study: NCT04905030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information C
Description: A4 information sheet containing a reminder of the upcoming HPV vaccination, and information on the history and characteristics of the Swedish national vaccination program.
Study: NCT06382961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Combining with 3 μg.kg-1 sufentanil, 3 μg.kg-1 dexmedetomidine is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil injection
Description: 3 μg.kg-1 sufentanil is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.
Study: NCT03307018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative systematic bronchial aspiration.
Description: Postoperative flexible bronchoscopy and systematic bronchial aspiration.
Study: NCT05725200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study: NCT05876988

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Chinese acupuncture
Description: Disposable acupuncture needles(0.30mm in diameter and 25-40mm in length) will be inserted at a depth of 10-30mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation was additionally delivered on the 6 pairs of the frontal acupoints. The output peak current and voltage of the machine would be 6V and 48mA, respectively, with constant wave at frequency of 2Hz and phase duration of 100µs for 30min. Electrical stimulation lasted 30min. The needles on body acupoints will be also retained for 30min.~Acupuncture intervention will be conducted for 2 sessions per week over 8 consecutive weeks. The determination of 8 weeks of the treatment duration will be based on the fact that the robust eﬀects of acupuncture in cancer patients will be generally observed within 8 weeks of treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chinese acupuncture
Description: Disposable acupuncture needles(0.30mm in diameter and 25-40mm in length) will be inserted at a depth of 10-30mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation was additionally delivered on the 6 pairs of the frontal acupoints. The output peak current and voltage of the machine would be 6V and 48mA, respectively, with constant wave at frequency of 2Hz and phase duration of 100µs for 30min. Electrical stimulation lasted 30min. The needles on body acupoints will be also retained for 30min.~Acupuncture intervention will be conducted for 2 sessions per week over 8 consecutive weeks. The determination of 8 weeks of the treatment duration will be based on the fact that the robust eﬀects of acupuncture in cancer patients will be generally observed within 8 weeks of treatment.
Study: NCT05482412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous (superficial) afferent electrical nerve stimulation specific for vagus nerve
Description: Direct superficial auricular sensory branch of Cr X \[Cranial Nerve Ten Vagus\]
Study: NCT05581355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal breathing training
Description: In the sleep center, it is carried out in a one-on-one manner by the trainer. At home, self-training through abdominal breathing training videos (10 minutes per day, you can accumulate up to 10 minutes in divided doses)
Study: NCT05482412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous (superficial) afferent electrical nerve stimulation specific for vagus nerve
Description: Direct superficial auricular sensory branch of Cr X \[Cranial Nerve Ten Vagus\]

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous (superficial) afferent electrical nerve stimulation specific for vagus nerve
Description: Direct superficial auricular sensory branch of Cr X \[Cranial Nerve Ten Vagus\]

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous (superficial) afferent electrical nerve stimulation specific for vagus nerve
Description: Direct superficial auricular sensory branch of Cr X \[Cranial Nerve Ten Vagus\]
Study: NCT04563611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Turkish Get-up exercise
Description: TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Askling L-Protocol
Description: he protocol consists of 3 different exercises. These are exercise 1 aimed at increasing flexibility, exercise 2 providing strength and trunk / pelvis stabilization, and exercise 3 aiming at specific strengthening. Pain is not allowed to be provoked when performing the exercises.
Study: NCT06790732

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Patients received sham PENG block (just 1mL saline).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine + Dexamethasone
Description: Patients received real PENG block (15 mL of bupivacaine 0.25% +0.2mg/mL dexamethasone).
Study: NCT05797818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Methylene Blue Only
Description: All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Methylene Blue (0.01%) + 4 minutes of light treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate Only
Description: All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Chlorhexidine gluconate (0.25%) + 4 minutes of light treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Methylene Blue + Chlorhexidine Gluconate
Description: All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Methylene blue (0.01%) + chlorhexidine gluconate (0.25%) + 4 minutes of light treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Only
Description: All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- 4 minutes of light treatment only
Study: NCT04563611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise
Description: To perform this exercise, participants will be asked to stand in an upright position on their knees. Hands and arms will be positioned on the chest and the individuals will be held by the physiotherapist at their heels. The individual will then be asked to lower the upper body forward as slowly as possible. Verbal commands will be given throughout the movement so that the hip and trunk smoothness is not disturbed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
Study: NCT06045143

Intervention type: DEVICE
Intervention: Patients undergoing DDD pacemaker implantation
Description: compare the effect right ventricular apical versus septal pacing on left ventricular function by deformation imaging using 2D speckle tracking echocardiography.

Intervention type: DEVICE
Intervention: Patients undergoing DDD pacemaker implantation
Description: compare the effect right ventricular apical versus septal pacing on left ventricular function by deformation imaging using 2D speckle tracking echocardiography.
Study: NCT04884529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chair-yoga program
Description: 8-week chair yoga program with gentle postures, breathing techniques, and mindfulness.
Study: NCT06450457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polar H10 heart rate monitor
Description: Heart rate will be monitored utilizing a Polar H10 heart rate monitor, with the goal of reaching moderate to high intensity for 30 minutes during the one hour long therapy intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therastride Treadmill System
Description: Participants will be asked to walk on the Therastride Treadmill for 30 minutes.This treadmill can unweight patients so that the task of walking becomes easier. The treadmill's body weight can be adjusted depending on how much assistance a patient needs from 0% of their bodyweight (completely independent) to up to 50% of their bodyweight for the purposes of this study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VECTOR Bioness
Description: Participants will be asked to walk using the VECTOR Bioness on a track outside the gym with a harness attached to an overhead sling system. This system can unweight patients so that the task of walking becomes easier. The body weight can be adjusted depending on how much assistance a patient needs from 0% of their bodyweight (completely independent) to up to 50% of their bodyweight for the purposes of this study. This system allows for overground walking on a small indoor track as opposed to walking on a treadmill.